Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2021

1 PROteolysis Targeting Chimera (PROTAC) Market Overview

• 1.1 Product Overview and Scope of PROteolysis Targeting Chimera (PROTAC)
• 1.2 PROteolysis Targeting Chimera (PROTAC) Segment by Type
  • 1.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 ARV-110
  • 1.2.3 ARV-471
  • 1.2.4 KYM-001
  • 1.2.5 Others
• 1.3 PROteolysis Targeting Chimera (PROTAC) Segment by Application
  • 1.3.1 PROteolysis Targeting Chimera (PROTAC) Sales Comparison by Application: (2021-2027)
  • 1.3.2 Oncology
  • 1.3.3 Others
• 1.4 Global PROteolysis Targeting Chimera (PROTAC) Market Size Estimates and Forecasts
  • 1.4.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue 2016-2027
  • 1.4.2 Global PROteolysis Targeting Chimera (PROTAC) Sales 2016-2027
  • 1.4.3 PROteolysis Targeting Chimera (PROTAC) Market Size by Region: 2016 Versus 2021 Versus 2027

2 PROteolysis Targeting Chimera (PROTAC) Market Competition by Manufacturers

• 2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global PROteolysis Targeting Chimera (PROTAC) Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers PROteolysis Targeting Chimera (PROTAC) Manufacturing Sites, Area Served, Product Type
• 2.5 PROteolysis Targeting Chimera (PROTAC) Market Competitive Situation and Trends
  • 2.5.1 PROteolysis Targeting Chimera (PROTAC) Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest PROteolysis Targeting Chimera (PROTAC) Players Market Share by Revenue
  • 2.5.3 Global PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario by Region

• 3.1 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
  • 3.3.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Country
  • 3.3.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
  • 3.4.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country
  • 3.4.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Region
  • 3.5.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region
  • 3.5.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
  • 3.6.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country
  • 3.6.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country
  • 3.7.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Type

• 4.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2016-2021)
• 4.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2016-2021)
• 4.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2016-2021)

5 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Application

• 5.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2016-2021)
• 5.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2016-2021)
• 5.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Arvinas
  • 6.1.1 Arvinas Corporation Information
  • 6.1.2 Arvinas Description and Business Overview
  • 6.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Arvinas Product Portfolio
  • 6.1.5 Arvinas Recent Developments/Updates
• 6.2 Kymera
  • 6.2.1 Kymera Corporation Information
  • 6.2.2 Kymera Description and Business Overview
  • 6.2.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Kymera Product Portfolio
  • 6.2.5 Kymera Recent Developments/Updates
• 6.3 C4 therapeutics
  • 6.3.1 C4 therapeutics Corporation Information
  • 6.3.2 C4 therapeutics Description and Business Overview
  • 6.3.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 C4 therapeutics Product Portfolio
  • 6.3.5 C4 therapeutics Recent Developments/Updates
• 6.4 Captor therapeutics
  • 6.4.1 Captor therapeutics Corporation Information
  • 6.4.2 Captor therapeutics Description and Business Overview
  • 6.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Captor therapeutics Product Portfolio
  • 6.4.5 Captor therapeutics Recent Developments/Updates
• 6.5 Vividion
  • 6.5.1 Vividion Corporation Information
  • 6.5.2 Vividion Description and Business Overview
  • 6.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Vividion Product Portfolio
  • 6.5.5 Vividion Recent Developments/Updates
• 6.6 Cullgen
  • 6.6.1 Cullgen Corporation Information
  • 6.6.2 Cullgen Description and Business Overview
  • 6.6.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Cullgen Product Portfolio
  • 6.6.5 Cullgen Recent Developments/Updates
• 6.7 Pfizer
  • 6.6.1 Pfizer Corporation Information
  • 6.6.2 Pfizer Description and Business Overview
  • 6.6.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Pfizer Product Portfolio
  • 6.7.5 Pfizer Recent Developments/Updates
• 6.8 Merck
  • 6.8.1 Merck Corporation Information
  • 6.8.2 Merck Description and Business Overview
  • 6.8.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Merck Product Portfolio
  • 6.8.5 Merck Recent Developments/Updates
• 6.9 Genentech
  • 6.9.1 Genentech Corporation Information
  • 6.9.2 Genentech Description and Business Overview
  • 6.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Genentech Product Portfolio
  • 6.9.5 Genentech Recent Developments/Updates
• 6.10 AstraZeneca
  • 6.10.1 AstraZeneca Corporation Information
  • 6.10.2 AstraZeneca Description and Business Overview
  • 6.10.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 AstraZeneca Product Portfolio
  • 6.10.5 AstraZeneca Recent Developments/Updates
• 6.11 Amgen
  • 6.11.1 Amgen Corporation Information
  • 6.11.2 Amgen PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
  • 6.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Amgen Product Portfolio
  • 6.11.5 Amgen Recent Developments/Updates
• 6.12 Bayer
  • 6.12.1 Bayer Corporation Information
  • 6.12.2 Bayer PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
  • 6.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Bayer Product Portfolio
  • 6.12.5 Bayer Recent Developments/Updates

7 PROteolysis Targeting Chimera (PROTAC) Manufacturing Cost Analysis

• 7.1 PROteolysis Targeting Chimera (PROTAC) Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of PROteolysis Targeting Chimera (PROTAC)
• 7.4 PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 PROteolysis Targeting Chimera (PROTAC) Distributors List
• 8.3 PROteolysis Targeting Chimera (PROTAC) Customers

9 PROteolysis Targeting Chimera (PROTAC) Market Dynamics

• 9.1 PROteolysis Targeting Chimera (PROTAC) Industry Trends
• 9.2 PROteolysis Targeting Chimera (PROTAC) Growth Drivers
• 9.3 PROteolysis Targeting Chimera (PROTAC) Market Challenges
• 9.4 PROteolysis Targeting Chimera (PROTAC) Market Restraints

10 Global Market Forecast

• 10.1 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
• 10.2 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
• 10.3 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List